KR20240028451A - Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제 - Google Patents

Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제 Download PDF

Info

Publication number
KR20240028451A
KR20240028451A KR1020247003085A KR20247003085A KR20240028451A KR 20240028451 A KR20240028451 A KR 20240028451A KR 1020247003085 A KR1020247003085 A KR 1020247003085A KR 20247003085 A KR20247003085 A KR 20247003085A KR 20240028451 A KR20240028451 A KR 20240028451A
Authority
KR
South Korea
Prior art keywords
cancer
bap1
pbrm1
tumor
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247003085A
Other languages
English (en)
Korean (ko)
Inventor
가즈노리 사에키
데이비드 웨이지스
킨 층
필립 잰쿠
Original Assignee
후지필름 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지필름 가부시키가이샤 filed Critical 후지필름 가부시키가이샤
Publication of KR20240028451A publication Critical patent/KR20240028451A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247003085A 2021-07-29 2022-07-28 Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제 Pending KR20240028451A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163227035P 2021-07-29 2021-07-29
US63/227,035 2021-07-29
PCT/JP2022/029062 WO2023008511A1 (ja) 2021-07-29 2022-07-28 Ｂａｐ１およびｐｂｒｍ１の少なくとも１つの機能低下を有する腫瘍に対する医薬組成物および抗腫瘍剤

Publications (1)

Publication Number Publication Date
KR20240028451A true KR20240028451A (ko) 2024-03-05

Family

ID=85087010

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247003085A Pending KR20240028451A (ko) 2021-07-29 2022-07-28 Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제

Country Status (6)

Country Link
US (1) US20240207301A1 (https=)
EP (1) EP4378466A4 (https=)
JP (1) JPWO2023008511A1 (https=)
KR (1) KR20240028451A (https=)
CN (1) CN117794548A (https=)
WO (1) WO2023008511A1 (https=)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038001A1 (en) 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES
WO2011074484A1 (en) 2009-12-18 2011-06-23 Libramedicina, Inc. PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES
WO2013146833A1 (ja) 2012-03-28 2013-10-03 富士フイルム株式会社 １－（２－デオキシ－２－フルオロ－４－チオ－β－Ｄ－アラビノフラノシル）シトシンの塩
WO2014027658A1 (ja) 2012-08-13 2014-02-20 富士フイルム株式会社 １－（２－デオキシ－２－フルオロ－４－チオ－β－Ｄ－アラビノフラノシル）シトシンの合成中間体およびチオヌクレオシドの合成中間体ならびにそれらの製造法
WO2016068341A1 (ja) 2014-10-31 2016-05-06 富士フイルム株式会社 チオヌクレオシド誘導体またはその塩および医薬組成物
WO2017150511A1 (ja) 2016-02-29 2017-09-08 富士フイルム株式会社 液状医薬製剤
WO2018043530A1 (ja) 2016-08-31 2018-03-08 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2019146129A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 イソクエン酸デヒドロゲナーゼ変異を有する腫瘍に対する医薬組成物および抗腫瘍剤ならびにその利用
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法
WO2019164010A1 (ja) 2018-02-26 2019-08-29 富士フイルム株式会社 膀胱がん用抗腫瘍剤および膀胱がんの処置方法
WO2019176985A1 (ja) 2018-03-13 2019-09-19 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2019176984A1 (ja) 2018-03-13 2019-09-19 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997038001A1 (en) 1996-04-09 1997-10-16 Yamasa Corporation 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINES
WO2011074484A1 (en) 2009-12-18 2011-06-23 Libramedicina, Inc. PROCESS FOR PREPARING SUBSTITUTED 1-O-ACYL-2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSES
WO2013146833A1 (ja) 2012-03-28 2013-10-03 富士フイルム株式会社 １－（２－デオキシ－２－フルオロ－４－チオ－β－Ｄ－アラビノフラノシル）シトシンの塩
WO2014027658A1 (ja) 2012-08-13 2014-02-20 富士フイルム株式会社 １－（２－デオキシ－２－フルオロ－４－チオ－β－Ｄ－アラビノフラノシル）シトシンの合成中間体およびチオヌクレオシドの合成中間体ならびにそれらの製造法
WO2016068341A1 (ja) 2014-10-31 2016-05-06 富士フイルム株式会社 チオヌクレオシド誘導体またはその塩および医薬組成物
WO2017150511A1 (ja) 2016-02-29 2017-09-08 富士フイルム株式会社 液状医薬製剤
WO2018043530A1 (ja) 2016-08-31 2018-03-08 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2019146129A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 イソクエン酸デヒドロゲナーゼ変異を有する腫瘍に対する医薬組成物および抗腫瘍剤ならびにその利用
WO2019146130A1 (ja) 2018-01-29 2019-08-01 富士フイルム株式会社 胆道がん用抗腫瘍剤および胆道がんの処置方法
WO2019164010A1 (ja) 2018-02-26 2019-08-29 富士フイルム株式会社 膀胱がん用抗腫瘍剤および膀胱がんの処置方法
WO2019176985A1 (ja) 2018-03-13 2019-09-19 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
WO2019176984A1 (ja) 2018-03-13 2019-09-19 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット

Also Published As

Publication number Publication date
EP4378466A4 (en) 2024-11-20
EP4378466A1 (en) 2024-06-05
CN117794548A (zh) 2024-03-29
US20240207301A1 (en) 2024-06-27
JPWO2023008511A1 (https=) 2023-02-02
WO2023008511A1 (ja) 2023-02-02

Similar Documents

Publication Publication Date Title
US20230146638A1 (en) Treatment of EGFR-Driven Cancer with Fewer Side Effects
EP4467154A1 (en) Medicine for treating or preventing cancer
JP2021512101A (ja) 肥満細胞症の治療のための併用療法
CA2869557A1 (en) Novel compositions of combinations of non-covalent dna binding agents and anti-cancer and/or anti-inflammatory agents and their use in disease treatment
CN112807434A (zh) Perk抑制剂在制备肝癌药物的增效剂中的应用
US20240139196A1 (en) Combination treatments in difficult to treat patients with advanced and/or metastatic trop-2 overexpressing cancers
EP2996692B1 (en) Means and methods for treating cancer
KR20240028451A (ko) Bap1 및 pbrm1 중 적어도 하나의 기능 저하를 갖는 종양에 대한 의약 조성물 및 항종양제
US20200352973A1 (en) Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
US7863255B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
WO2024160057A1 (zh) 长效β2AR激动剂在制备治疗癌症药物中的应用
US20230390277A1 (en) Methods to sensitize tumors to treatment by immunotherapy
AU2005279344B2 (en) Use of midostaurin for treating gastrointestinal stromal tumors
HK40106737A (zh) 针对bap1及pbrm1中的至少一个的功能下降的肿瘤的药物组合物及抗肿瘤剂
WO2019146129A1 (ja) イソクエン酸デヒドロゲナーゼ変異を有する腫瘍に対する医薬組成物および抗腫瘍剤ならびにその利用
WO2025154819A1 (ja) くも膜下出血発症後の二次性脳損傷の予防薬
Pokharel Preclinical Assessment of Dihydroquinolinone Inhibitors Directly Targeting Oncogene TFCP2 as Cancer Therapeutics
IL323919A (en) Administration of a beta-catenin antagonist and methods of use
CN118434422A (zh) 抗体-药物缀合物和rasg12c抑制剂的组合
KR20190077998A (ko) Tpx-0005를 유효성분으로 포함하는 대장암 예방 또는 치료용 약학적 조성물
JP2010111582A (ja) リファンピシンを成分とする肝臓癌治療剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902